Global Overactive Bladder Treatment Market

Dec 2018| VMR499A| Verified Market Research

Report Highlights

The global Overactive Bladder Treatment market was valued at USD 3.44 billion in 2016 and is projected to reach USD 4.43 billion by 2025, growing at a CAGR of 2.84% from 2017 to 2025.

An overactive bladder causes a sudden urge to urinate. It can also trigger involuntary loss of urine, known as incontinence. Overactive bladder affects mostly women and geriatric population. The health issue is highly prevalent and the market is expected to grow during the forecast period.

Market Dynamics:
1. Market Drivers
1.1 Improved innovations in Intravesical therapies
1.2 High level marketing by pharma companies
1.3 Increase geriatric population
1.4 Rising number of cases of Diseases Characterized By OAB
2. Market Restraints
2.1 Undesired Systemic Effects of Current OAB Treatments

Market Segmentation:
1. By Disease:
1.1 Idiopathic Overactive Bladder  
1.2 Neurogenic Overactive Bladder
1.2.1 Overactive Bladder in Parkinson's Disease
1.2.2 Overactive Bladder in Stroke
1.2.3 Overactive Bladder in Multiple Sclerosis
1.2.4 Overactive Bladder in Spinal Cord Injury
1.2.5 Overactive Bladder in Other Disorders

2. By Pharmacotherapy:
2.1 Anticholinergics
2.1.1 Solifenacin
2.1.2 Oxybutynin
2.1.3 Fesoterodine
2.1.4 Darifenacin
2.1.5 Tolterodine
2.1.6 Trospium
2.1.7 Other Anticholinergics
2.2 Mirabegron
2.3 Botox
2.4 Neurostimulation
2.5 Intravesical Instillation

3. By Region:
3.1 North America (U.S., Canada, Mexico)
3.2 Europe (Germany, UK, France, Rest of Europe)
3.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
3.4 Latin America (Brazil, Argentina, Rest of Latin America)
3.5 Middle East & Africa

Competitive Landscape:
The major players in the market are as follows:
1. Astellas Pharma Inc.
2. Pfizer, Inc.  
3. Teva Pharmaceutical Industries Limited  
4. Allergan, PLC.  
5. Mylan N.V.  
6. Endo International PLC  
7. Hisamitsu Pharmaceutical Co., Inc.
8. Sanofi
9. Aurobindo Pharma Limited  
10. Johnson & Johnson
11. Intas Pharmaceuticals Ltd.  
12. Apotex Inc.  
13. Macleods Pharmaceuticals Ltd.  
14. Medtronic PLC
15. Cogentix Medical, Inc.
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Research study on the Overactive Bladder Treatmentmarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.

To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.

Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.

Verified Market Research
Price: $3950

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.